期刊
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
卷 50, 期 10, 页码 1733-1742出版社
WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2011-0902
关键词
biomarkers; cancer; DNA methylation; hypomethylation
资金
- FICYT [BP11138]
- IUOPA
- Miguel Servet program
- Spanish Ministry of Health [PI061267, PS09/02454]
- Spanish National Research Council [CSIC 200820I172]
- Community of Asturias [FICYT IB09-106]
- Obra Social Cajastur, Spain
DNA methylation is one of the best-known epigenetic modifications in mammals. The alteration of DNA methylation patterns has been found to be related to many diseases, including cancer. It is well-known that during carcinogenesis, a site-specific DNA hypermethylation and a global DNA hypomethylation take place. This overall loss of DNA methylation has been proposed as a valid biomarker for cancer. Given its medical utility, in recent years it has become apparent that there is a need to develop methods for the analysis of DNA methylation using different approaches: global, locus-specific, or genome-wide. Here we review some of these techniques and discuss their potential clinical utility.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据